Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 12/20 | 0.49 |
| ▸ | PPARA | Q07869 | 11/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15851102 | 1.00 | NPC1 (0.50) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL10102036 | 0.89 | NPC1 (0.50) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL10101741 | 0.89 | S1PR1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL10102030 | 0.81 | SMN1; SMN2 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPK1 | |
| SCHEMBL15255539 | 0.81 | NPC1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL7674107 | 0.81 | NPC1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL15851161 | 0.80 | NPC1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL17217588 | 0.80 | NPC1 (0.48) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL4451421 | 0.80 | L3MBTL1 (0.71) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG | |
| SCHEMBL19733323 | 0.80 | L3MBTL1 (0.71) | NPC1RAB9AL3MBTL1SMN1; SMN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | NPC1 4422/4885RAB9A 2827/4885L3MBTL1 4039/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | NPC1 896/4885RAB9A 997/4885L3MBTL1 4864/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | NPC1 978/4885RAB9A 1124/4885L3MBTL1 4861/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | NPC1 978/4885RAB9A 1124/4885L3MBTL1 4861/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | NPC1 4521/4885RAB9A 2704/4885L3MBTL1 3903/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | NPC1 4551/4885RAB9A 2770/4885L3MBTL1 3917/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | NPC1 2599/4885RAB9A 3815/4885L3MBTL1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.